Literature DB >> 6420048

Effects of alpha-difluoromethylornithine on the growth of 9L rat brain tumor multicellular spheroids and their response to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Y Sano, D F Deen, S M Oredsson, L J Marton.   

Abstract

9L rat brain tumor cell spheroids were treated with alpha-difluoromethylornithine (DFMO) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) alone and in combination. In contrast to results obtained with 9L monolayer culture cells, very low concentrations of DFMO killed spheroid cell within 0.5 day after the start of treatment; cell kill was maximum within 2 to 3 days. DFMO cytotoxicity could be prevented by adding putrescine (to a final concentration of 1 mM) to the culture medium. DFMO also significantly slowed and eventually stopped the growth of spheroids in a dose-dependent manner. Cells in all regions of DFMO-pretreated spheroids were sensitized to BCNU as measured by colony-forming efficiency; this sensitization was prevented when putrescine was added to culture medium before BCNU treatment. When used as single agents, either a 3-day treatment with 10 mM DFMO or a 1-hr treatment with BCNU (1.5 micrograms/ml) produced similar growth delay, but used in combination, the two agents produced a much longer growth delay than produced by either agent alone. Growth of spheroids treated continuously for up to 28 days with 10 mM DFMO ceased at approximately 7 times the volume at the time of treatment. When spheroid cells were treated for 1 hr with BCNU (1.5 micrograms/ml) and then were treated continuously with DFMO, growth plateaued at approximately 3.5 times the volume at the time of treatment; when spheroids were treated first with DFMO for 3 days, then with BCNU (1.5 micrograms/ml) for 1 hr, and then treated continuously with DFMO, growth plateaued at approximately 1.5 times the volume at the time of treatment. The number of clonogenic cells per spheroid that survived combination treatment also reflected the cytotoxic effects of the two drugs. Thus, the combined drug treatment was very effective in inhibiting the growth of spheroids and in preventing an increase in the number of clonogenic cells per spheroid.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420048

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Recent advances in the biochemistry of polyamines in eukaryotes.

Authors:  A E Pegg
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

2.  The growth-inhibitory effect of 4-hydroperoxycyclophosphamide against human non-small cell lung carcinoma is enhanced by low-dose difluoromethylornithine.

Authors:  D C Tsai; G D Luk
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Heterogeneous survival responses of human gastric cancer clones to alpha difluoromethylornithine in vitro.

Authors:  S C Barranco; P J Ford; C M Townsend
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  Cell cycle kinetics responses of human stomach cancer cells to reduction in polyamine levels by treatment with alpha difluoromethylornithine in vitro.

Authors:  S C Barranco; P J Ford; C M Townsend
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

5.  A phase II study of alpha-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma.

Authors:  F L Meyskens; E M Kingsley; T Glattke; L Loescher; A Booth
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Polyamines in clinical disorders.

Authors:  D F Tierney; L J Marton; A D Hacker; N Lowe
Journal:  West J Med       Date:  1985-01

Review 7.  Multicellular spheroids. A review on cellular aggregates in cancer research.

Authors:  W Mueller-Klieser
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

8.  Polyamine-DNA Interactions: Possible Site of New Cancer Chemotherapeutic Intervention.

Authors:  L J Marton; B G Feuerstein
Journal:  Pharm Res       Date:  1986-12       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.